Therefore, PD-1/PD-L1 blockade may reverse the immune-evasive state into an antitumor response state, providing a rationale for treating MSI-H/dMMR GC patients with ICIs targeting PD-1/PD-L1. Here, CD274 is linked to gastric cancer.